KLOW Blend Research Overview

Core Research

KLOW Blend Research Overview

Laboratory & Research Guide

Klow Research Compound Overview

Research-only overview of Klow 80mg, with product documentation and laboratory-use boundaries.

Research-Only Notice & Compliance Boundary

This document is compiled strictly for educational and analytical reference purposes within laboratory, academic, and clinical research settings. The compounds discussed herein are supplied strictly as Research Use Only (RUO) chemicals and are not intended for human or veterinary consumption, diagnostic use, or therapeutic administration. Core Research does not provide dosing, reconstitution, or clinical administration guidelines.

Scientific Context and Research Background of Klow

Klow research compound is a precisely engineered, quad-peptide lyophilised blend supplied in an 80mg format, representing one of the most compositionally complex multi-peptide research preparations currently available within the RUO sector. Designed exclusively for controlled laboratory investigation, Klow integrates four biochemically distinct peptide entities — BPC-157, TB-500, GHK-Cu, and KPV — into a single, analytically verified vial.

What makes Klow particularly compelling from a research standpoint is not merely the identity of its constituent peptides, but the deliberate rationale behind their co-formulation. Each of the four components has accumulated an independent body of pre-clinical literature spanning cytoprotection, extracellular matrix remodelling, angiogenic signalling, and anti-inflammatory pathway modulation. When a researcher encounters Klow 80mg in a laboratory context, they are not simply handling four separate peptides in proximity — they are engaging with a formulation architecture that has been engineered to preserve the structural and functional integrity of each component simultaneously, despite their markedly divergent physicochemical profiles.

The research significance of Klow extends beyond its compositional novelty. In an era where multi-target peptide research is gaining traction across disciplines including regenerative biology, wound-healing pharmacology, and inflammatory cascade modelling, the availability of a rigorously characterised, co-lyophilised quad-blend addresses a genuine methodological gap. Investigators who previously required four separate reconstitution steps, four independent storage conditions, and four distinct quality-control assessments can now work from a single, homogenous preparation — provided that preparation has been manufactured to the exacting standards that multi-peptide co-formulation demands.

This overview document serves as the primary reference resource for researchers seeking to understand Klow’s entity identity, physicochemical characterisation, pre-clinical evidence landscape, and the specific analytical and operational decisions that underpin its manufacture at Core Research. All information presented herein is framed strictly within research-use boundaries and is intended to support informed, responsible laboratory practice.

Research Context Note: Klow (ID: O036) is catalogued within the Core Research compounds category and is subject to full documentation protocols including certificate of analysis, HPLC purity profiling, and mass spectrometry verification. Its 80mg format reflects the aggregate mass of all four constituent peptides across the lyophilised cake, not the mass of any single component.

Molecular Structure and Physicochemical Properties

The physicochemical characterisation of Klow 80mg is necessarily a composite exercise, requiring independent structural analysis of each of its four constituent peptides before any meaningful assessment of their co-formulated behaviour can be undertaken. The four components — BPC-157, TB-500 (Thymosin Beta-4 fragment), GHK-Cu (copper tripeptide-1), and KPV (Lys-Pro-Val) — span a wide range of molecular weights, charge states, solubility profiles, and secondary structural tendencies, making their co-formulation a non-trivial analytical challenge.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide comprising 15 amino acid residues with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its molecular formula is C62H98N16O22, yielding a molecular weight of approximately 1,419.5 Da. BPC-157 is characterised by a high proline content, which confers significant conformational rigidity and resistance to enzymatic degradation. It exhibits moderate aqueous solubility and is generally stable across a pH range of 4.0–7.0 under controlled conditions. Its isoelectric point (pI) falls in the mildly acidic range, and it carries a net negative charge at physiological pH.

TB-500, the synthetic analogue of the actin-sequestering domain of Thymosin Beta-4, corresponds to the fragment Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser (residues 17–23 of the full Thymosin Beta-4 sequence in its commercially relevant truncated form). The molecular weight of the relevant TB-500 research fragment is approximately 2,888 Da. Critically for formulation purposes, TB-500 exhibits pronounced hydrophobic character due to its leucine, isoleucine, and phenylalanine residues, and demonstrates limited aqueous solubility at neutral pH without co-solvent assistance. This hydrophobicity is the primary physicochemical tension point within the Klow blend.

GHK-Cu (Copper Tripeptide-1, glycyl-L-histidyl-L-lysine copper complex) is a low-molecular-weight tripeptide-metal complex with the molecular formula C14H24CuN6O4 and a molecular weight of approximately 403.9 Da. GHK-Cu is highly hydrophilic, carrying a stable square-planar copper(II) coordination complex that confers both its characteristic blue colouration and its strong affinity for aqueous environments. Its water solubility exceeds 50 mg/mL under standard laboratory conditions, and it is stable across a broad pH range. The stark contrast between GHK-Cu’s hydrophilicity and TB-500’s hydrophobicity represents the central formulation challenge that defines Klow’s manufacturing complexity.

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), with the molecular formula C16H30N4O4 and a molecular weight of approximately 342.4 Da. KPV is amphipathic in character, with the lysine residue contributing a positively charged amine group at physiological pH and the valine residue contributing modest hydrophobic character. Its small size renders it relatively stable under lyophilisation conditions, though its interaction with the copper ion of GHK-Cu in co-formulated systems warrants careful monitoring during analytical characterisation.

Component Residues / Formula Approx. MW (Da) Solubility Profile Key Structural Feature
BPC-157 15 AA; C₆₂H₉₈N₁₆O₂₂ ~1,419.5 Moderate aqueous High Pro content; conformational rigidity
TB-500 ~43 AA fragment ~2,888 Hydrophobic; limited aqueous Leu/Ile/Phe hydrophobic core
GHK-Cu Tripeptide-Cu²⁺; C₁₄H₂₄CuN₆O₄ ~403.9 Highly hydrophilic (>50 mg/mL) Square-planar Cu(II) coordination
KPV Tripeptide; C₁₆H₃₀N₄O₄ Comparative Analysis and Specifications

Understanding Klow 80mg within the broader landscape of RUO peptide preparations requires a structured comparison of its defining technical parameters. The following specifications reflect the analytical standards applied during manufacture and quality-control verification at Core Research, and are presented here to assist researchers in contextualising Klow’s performance profile relative to standard single-peptide RUO benchmarks.

Parameter Specification / Standard Research Relevance
HPLC Purity (per component) ≥98.0% for each of the four constituent peptides, verified by reverse-phase HPLC with UV detection at 214 nm and 280 nm Ensures that observed biological activity in pre-clinical assays is attributable to the target peptide sequence rather than synthesis-derived impurities or truncated fragments
Mass Spectrometry Verification ESI-MS or MALDI-TOF confirmation of molecular ion peaks within ±0.1 Da of theoretical monoisotopic mass for all four components; isotope pattern matching required Provides unambiguous sequence-level identity confirmation, particularly critical for TB-500 given its larger fragment size and susceptibility to oxidative methionine modification during storage
Lyophilisation Stability & Storage Lyophilised cake stable at −20°C for ≥24 months under desiccated, light-protected conditions; post-reconstitution stability assessed at 4°C over 72-hour window Multi-peptide co-lyophilisation introduces differential degradation kinetics; stability data informs experimental scheduling and ensures researchers do not inadvertently work with partially degraded preparations
Endotoxin & Sterility Testing LAL (Limulus Amebocyte Lysate) endotoxin testing to <1 EU/mg; sterility confirmed by USP <71> membrane filtration method prior to batch release Essential for in vitro cell-based assays where endotoxin contamination would confound inflammatory pathway readouts — particularly relevant given KPV’s anti-inflammatory signalling profile and GHK-Cu’s cytokine modulation activity

Analytical Note: The co-formulated nature of Klow 80mg necessitates that HPLC chromatographic methods be optimised with gradient conditions capable of resolving all four peptide peaks within a single analytical run. Researchers are advised to consult the accompanying Certificate of Analysis for retention time data and to validate their in-house HPLC method against the reference chromatogram provided with each batch.

Regulatory Status and Safety Compliance

Although Klow 80mg is supplied exclusively as a Research Use Only compound and carries no clinical or therapeutic designation, Core Research operates within a governance framework that reflects the highest standards of scientific accountability, regulatory compliance, and institutional responsibility. The following principles govern all aspects of compound supply, documentation, and researcher engagement.

Regulatory Compliance: All compounds supplied by Core Research, including Klow 80mg, are manufactured and documented in accordance with applicable RUO regulatory frameworks. In the United Kingdom, this includes adherence to the Human Medicines Regulations 2012 (as amended), which explicitly delineates the boundary between research-use chemicals and medicinal products. Klow is not classified as a medicinal product, is not licensed by the Medicines and Healthcare products Regulatory Agency (MHRA), and must not be represented or utilised as such. Researchers operating within academic or commercial laboratory settings are responsible for ensuring that their use of Klow complies with their institutional ethics approvals, local regulatory requirements, and any applicable Home Office licensing conditions where animal research is involved.

Professional Standards — GMC and HCPC Alignment: Where Klow documentation is accessed by registered healthcare professionals — including those registered with the General Medical Council (GMC) or the Health and Care Professions Council (HCPC) — it is emphasised that the compound’s RUO status is incompatible with clinical prescription, patient administration, or any activity that would constitute the practice of medicine or a regulated health profession. Healthcare professionals are reminded of their duty under their respective professional codes to act within their scope of practice and to avoid facilitating the misuse of research compounds.

Safeguarding — Adults and Children: Core Research maintains a zero-tolerance position regarding the supply of RUO compounds to individuals who may seek to use them for self-administration or administration to vulnerable persons, including children. Any communication or order that raises concern regarding intended non-research use is subject to immediate review under Core Research’s safeguarding escalation protocol. Researchers who become aware of potential misuse within their institutional environment are encouraged to report concerns through their institution’s designated safeguarding lead or, where appropriate, directly to statutory authorities.

Data Protection: All researcher and institutional data processed in connection with Klow orders, documentation requests, and technical enquiries is handled in strict accordance with the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018. Core Research does not share researcher data with third parties for commercial purposes, and all data is retained only for the duration necessary to fulfil regulatory and contractual obligations.

Secure Reporting: Concerns regarding compound integrity, suspected adulteration, adverse analytical findings, or potential misuse may be reported securely via Core Research’s confidential reporting channel. All reports are reviewed by the compliance team within 48 working hours, and reporters may remain anonymous where disclosure is not required by law.

Governance Reminder: Klow 80mg is not approved for, and must not be used in, any diagnostic, therapeutic, or prophylactic application in humans or animals. Misrepresentation of this compound’s regulatory status constitutes a serious compliance breach and may result in immediate suspension of supply and referral to relevant regulatory authorities.

Research Questions and Technical Support

The following questions represent the most common technical and operational enquiries received from researchers working with Klow 80mg in laboratory settings. Each response is framed strictly within RUO boundaries.

What is the recommended reconstitution solvent for Klow 80mg in a laboratory setting?

Bacteriostatic water or sterile phosphate-buffered saline (PBS) at pH 7.0–7.4 is typically employed for multi-peptide lyophilised blends. Researchers report that slow, dropwise addition along the vial wall, avoiding direct agitation, best preserves structural integrity across all four components.

Experiential note: Laboratory teams working with GHK-Cu-containing blends frequently observe a faint blue tint upon reconstitution — this is characteristic of the copper coordination complex and does not indicate degradation.

How should Klow 80mg be stored prior to and following reconstitution?

Prior to reconstitution, lyophilised Klow should be stored at −20°C in a desiccated, light-protected environment. Post-reconstitution aliquots should be maintained at 4°C and utilised within 72 hours. Freeze-thaw cycling of reconstituted solution is strongly discouraged to prevent aggregation.

Experiential note: Researchers consistently find that pre-aliquoting into single-use volumes immediately after reconstitution significantly reduces degradation risk across extended experimental programmes.

Can Klow 80mg be used in cell-based in vitro assays without further purification?

Yes, provided endotoxin levels are confirmed below assay-specific thresholds via the accompanying CoA. Researchers should validate that the co-formulated blend does not interfere with their specific assay readout, particularly fluorescence-based assays where copper may introduce background signal.

Experiential note: Teams conducting NF-κB reporter assays with KPV-containing preparations routinely include a copper-only vehicle control to isolate GHK-Cu’s independent contribution to observed signalling changes.

What analytical documentation is supplied with each batch of Klow 80mg?

Each batch is accompanied by a Certificate of